



GLP-1 Coverage Considerations

December 12, 2025; Last Updated April 6, 2026

Wegovy®

Effective January 1, 2026, Wegovy is no longer eligible for coverage for **weight loss** or **weight loss-related indications**.

Effective April 1, 2026, Wegovy does not require an approved prior authorization (PA) when prescribed for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). Claims not submitted with the appropriate *International Classification of Diseases – 10th Revision, Clinical Modification* (ICD-10-CM) diagnosis code (K76.0 and/or K75.8) will deny with **Reject Code 80 – Diagnosis Code Submitted Does Not Meet Drug Coverage Criteria**. PA requests submitted for non-weight loss-related indications, such as cardiovascular disease, will be reviewed for coverage consideration based on medical necessity.

Zepbound® and Saxenda®

Effective January 1, 2026, the following drugs have been removed from the [Medi-Cal Rx Contract Drugs List](#) (CDL) and are no longer eligible for coverage for **weight loss** or **weight loss-related indications**:

- Zepbound
- Saxenda

Effective January 1, 2026, claims for these drugs will deny with **Reject Code 70 – Product/Service Not Covered** regardless of indication. All previously approved PAs expired on December 31, 2025. PA requests for Zepbound will be considered when used for obstructive sleep apnea (OSA).

Other GLP-1 Drugs

The following GLP-1 drugs are currently on the CDL and continue to have a Code I diagnosis restriction of type 2 diabetes. Effective January 1, 2026, these drugs are no longer eligible for coverage for **weight loss** or **weight loss-related indications**:

- Ozempic®
- Rybelsus®
- Mounjaro®
- Victoza®
- Byetta
- Bydureon®
- Trulicity®

Claims for these seven drugs will continue to deny with Reject Code 80 when the Code I diagnosis restriction is not met. PA requests submitted for non-weight loss-related indications will be reviewed for coverage consideration based on medical necessity.

Note: Effective January 1, 2026, PA requests submitted for weight loss or weight loss-related indications will be reviewed for medical necessity for members younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.